{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:41:24Z","timestamp":1775580084304,"version":"3.50.1"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Aromatase inhibitors (AI) such as anastrozole, letrozole, and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor\u2013positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is extensive, and this phenomenon may have important ramification for AI-associated arthralgia, a common toxicity of which the etiology remains unclear. We speculated that hepatic uptake transporters involved in the elimination of AIs play a crucial role in explaining this pharmacologic variability. Using an array of in silico, in vitro, in vivo, and human studies, we identified OATP1B1 and OATP1B3 (in humans) as well as the murine ortholog Oatp1b2 as transporters that regulate the initial step in the elimination of AIs. Genetic deficiency of this transport mechanism in mice was associated with elevated plasma levels of AIs and with concurrent increases in treatment-related arthralgia. In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>AIs are effective but often discontinued because of arthralgia. This study explores the role of OATP1B transporters in AI-related side effects and the potential usage of transporter biomarkers to predict and reduce the risk of arthralgia associated with AI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0475","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:45:21Z","timestamp":1741592721000},"page":"497-511","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor\u2013Associated Arthralgia Susceptibility"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-7870","authenticated-orcid":false,"given":"Hanieh","family":"Taheri","sequence":"first","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-2332","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-3295","authenticated-orcid":false,"given":"Kevin M.","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-2630","authenticated-orcid":false,"given":"Eman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-3362","authenticated-orcid":false,"given":"Yan","family":"Jin","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1361-8654","authenticated-orcid":false,"given":"Thomas","family":"Drabison","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5785","authenticated-orcid":false,"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"2Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8737-2092","authenticated-orcid":false,"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-9437","authenticated-orcid":false,"given":"Nicholas A.","family":"Young","sequence":"additional","affiliation":[{"name":"3Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0381-9356","authenticated-orcid":false,"given":"Junan","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7396-3225","authenticated-orcid":false,"given":"Xiaolin","family":"Cheng","sequence":"additional","affiliation":[{"name":"2Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5584-6738","authenticated-orcid":false,"given":"Kara N.","family":"Corps","sequence":"additional","affiliation":[{"name":"4Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-9190","authenticated-orcid":false,"given":"Christopher C.","family":"Coss","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-3270","authenticated-orcid":false,"given":"Jennifer E.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-5645","authenticated-orcid":false,"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[{"name":"6Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-6644","authenticated-orcid":false,"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-7734","authenticated-orcid":false,"given":"Shuiying","family":"Hu","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2025051309001693500_bib1","doi-asserted-by":"crossref","first-page":"713700","DOI":"10.3389\/fendo.2021.713700","article-title":"Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management","volume":"12","author":"Hyder","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025051309001693500_bib2","first-page":"468S","article-title":"Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors","volume":"9","author":"Buzdar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025051309001693500_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdq337","article-title":"The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum","volume":"22","author":"L\u00f8nning","year":"2011","journal-title":"Ann Oncol"},{"key":"2025051309001693500_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/bjc.2011.58","article-title":"Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole\u2013of clinical importance?","volume":"104","author":"Geisler","year":"2011","journal-title":"Br J Cancer"},{"key":"2025051309001693500_bib5","doi-asserted-by":"crossref","first-page":"20503121221078722","DOI":"10.1177\/20503121221078722","article-title":"Aromatase inhibitor\u2013associated musculoskeletal pain: an overview of pathophysiology and treatment modalities","volume":"10","author":"Grigorian","year":"2022","journal-title":"SAGE Open Med"},{"key":"2025051309001693500_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14656566.8.2.119","article-title":"Pharmacogenetics and oncology treatment for breast cancer","volume":"8","author":"Marsh","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"2025051309001693500_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1099800419895114","article-title":"Genetic underpinnings of musculoskeletal pain during treatment with aromatase inhibitors for breast cancer: a biological pathway analysis","volume":"22","author":"Zhu","year":"2020","journal-title":"Biol Res Nurs"},{"key":"2025051309001693500_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/jcpt.12569","article-title":"Impact of the OATP 1B1 c. 521T&gt; C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers","volume":"42","author":"Gregory","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"2025051309001693500_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/tpj.2015.73","article-title":"Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study","volume":"16","author":"Rumiato","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"2025051309001693500_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/pgs-2019-0020","article-title":"Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole","volume":"20","author":"Dempsey","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2025051309001693500_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-017-4243-3","article-title":"SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway","volume":"164","author":"Dudenkov","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2025051309001693500_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3892\/or.2017.5727","article-title":"Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen","volume":"38","author":"Gao","year":"2017","journal-title":"Oncol Rep"},{"key":"2025051309001693500_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17425255.2022.2113380","article-title":"The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature","volume":"18","author":"Anabtawi","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025051309001693500_bib14","doi-asserted-by":"crossref","first-page":"124106","DOI":"10.1016\/j.jchromb.2024.124106","article-title":"Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS\/MS","volume":"1238","author":"Taheri","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025051309001693500_bib15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025051309001693500_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2010.06.012","article-title":"Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3","volume":"405","author":"Bednarczyk","year":"2010","journal-title":"Anal Biochem"},{"key":"2025051309001693500_bib17","doi-asserted-by":"crossref","first-page":"e21863","DOI":"10.1096\/fj.202100648R","article-title":"8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1","volume":"35","author":"Ungv\u00e1ri","year":"2021","journal-title":"FASEB J"},{"key":"2025051309001693500_bib18","doi-asserted-by":"crossref","first-page":"969363","DOI":"10.3389\/fphys.2022.969363","article-title":"Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3","volume":"13","author":"Schnegelberger","year":"2022","journal-title":"Front Physiol"},{"key":"2025051309001693500_bib19","doi-asserted-by":"crossref","first-page":"e0248579","DOI":"10.1371\/journal.pone.0248579","article-title":"Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: application of physiologically-based pharmacokinetic modeling to gain quantitative insights","volume":"16","author":"Arora","year":"2021","journal-title":"PLoS One"},{"key":"2025051309001693500_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cts.12630","article-title":"Interaction between sex and organic anion-transporting polypeptide 1b2 on the pharmacokinetics of regorafenib and its metabolites regorafenib-N-oxide and regorafenib-glucuronide in mice","volume":"12","author":"Fu","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2025051309001693500_bib21","doi-asserted-by":"crossref","first-page":"e3056","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio Protoc"},{"key":"2025051309001693500_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41422-023-00870-8","article-title":"Cryo-EM structures of human organic anion transporting polypeptide OATP1B1","volume":"33","author":"Shan","year":"2023","journal-title":"Cell Res"},{"key":"2025051309001693500_bib23","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41467-023-41552-8","article-title":"Structure of human drug transporters OATP1B1 and OATP1B3","volume":"14","author":"Ciut\u0103","year":"2023","journal-title":"Nat Commun"},{"key":"2025051309001693500_bib24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J Clin Invest"},{"key":"2025051309001693500_bib25","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/0008-5472.CAN-16-1492","article-title":"TRPA1 mediates aromatase inhibitor\u2013evoked pain by the aromatase substrate androstenedione","volume":"76","author":"De Logu","year":"2016","journal-title":"Cancer Res"},{"key":"2025051309001693500_bib26","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1038\/ncomms6736","article-title":"Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1","volume":"5","author":"Fusi","year":"2014","journal-title":"Nat Commun"},{"key":"2025051309001693500_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.gene.2013.11.091","article-title":"Pain assessment in animal models of osteoarthritis","volume":"537","author":"Piel","year":"2014","journal-title":"Gene"},{"key":"2025051309001693500_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-1619-1_13","article-title":"Assessment of knee joint pain in experimental rodent models of osteoarthritis","volume":"1226","author":"Piel","year":"2015","journal-title":"Methods Mol Biol"},{"key":"2025051309001693500_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cam4.1256","article-title":"Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm","volume":"7","author":"Reinbolt","year":"2018","journal-title":"Cancer Med"},{"key":"2025051309001693500_bib30","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3390\/pharmaceutics14091933","article-title":"A metabolomics approach for predicting OATP1B-type transporter-mediated drug-drug interaction liabilities","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025051309001693500_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0925-4439(02)00096-0","article-title":"Exemestane, a new steroidal aromatase inhibitor of clinical relevance","volume":"1587","author":"Lombardi","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"2025051309001693500_bib32","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/2767-9764.CRC-24-0332","article-title":"Systematic evaluation of tyrosine kinase inhibitors as OATP1B1 substrates using a competitive counterflow screen","volume":"4","author":"Drabison","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025051309001693500_bib33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3109\/00498250903171395","article-title":"Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes","volume":"39","author":"Murai","year":"2009","journal-title":"Xenobiotica"},{"key":"2025051309001693500_bib34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1078-0432.CCR-10-1980","article-title":"High impact of Oatp1a\/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel","volume":"17","author":"van de Steeg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025051309001693500_bib35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025051309001693500_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1535-7163.MCT-13-0541","article-title":"OATP1A\/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice","volume":"13","author":"Iusuf","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2025051309001693500_bib37","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.3390\/ijms21124355","article-title":"Overview of neurological mechanism of pain profile used for animal \u201cpain-like\u201d behavioral study with proposed analgesic pathways","volume":"21","author":"Yam","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025051309001693500_bib38","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.3390\/molecules26185500","article-title":"Endogenous biomarkers for SLC transporter-mediated drug-drug interaction evaluation","volume":"26","author":"Li","year":"2021","journal-title":"Molecules"},{"key":"2025051309001693500_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/mol.118.114314","article-title":"Organic anion transporting polypeptides: emerging roles in cancer pharmacology","volume":"95","author":"Schulte","year":"2019","journal-title":"Mol Pharmacol"},{"key":"2025051309001693500_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drup.2016.06.005","article-title":"The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: insights from knockout and humanized mice","volume":"27","author":"Durmus","year":"2016","journal-title":"Drug Resist Updat"},{"key":"2025051309001693500_bib41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2025051309001693500_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tips.2011.10.005","article-title":"Functions of OATP1A and 1B transporters in vivo: insights from mouse models","volume":"33","author":"Iusuf","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2025051309001693500_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejpb.2022.06.008","article-title":"ABCB1 restricts brain accumulation of the novel ROR\u03b3 agonist cintirorgon, while OATP1A\/1B and CYP3A limit its oral availability","volume":"177","author":"Li","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"2025051309001693500_bib44","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/acs.molpharmaceut.5b00453","article-title":"Preclinical mouse models to study human OATP1B1-and OATP1B3-mediated drug\u2013drug interactions in vivo","volume":"12","author":"Durmus","year":"2015","journal-title":"Mol Pharm"},{"key":"2025051309001693500_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2025051309001693500_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.114.057976","article-title":"Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins","volume":"42","author":"Salphati","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2025051309001693500_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.2012.106","article-title":"OATP1B1 polymorphism as a determinant of erythromycin disposition","volume":"92","author":"Lancaster","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2025051309001693500_bib48","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2125.2010.03791.x","article-title":"In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole","volume":"70","author":"Kamdem","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2025051309001693500_bib49","article-title":"Bioanalytical method validation guidance for industry","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"2025051309001693500_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/dmd.119.089474","article-title":"Alteration in the plasma concentrations of endogenous organic anion-transporting polypeptide 1B biomarkers in patients with non-small cell lung cancer treated with paclitaxel","volume":"48","author":"Mori","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"2025051309001693500_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dmpk.2018.09.003","article-title":"Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers","volume":"34","author":"Mori","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025051309001693500_bib52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2025051309001693500_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.acr.2022.02.006","article-title":"Strategies to mitigate the toxicity of cancer therapeutics","volume":"155","author":"Kahn","year":"2022","journal-title":"Adv Cancer Res"},{"key":"2025051309001693500_bib54","doi-asserted-by":"crossref","first-page":"102171","DOI":"10.1016\/j.ctrv.2021.102171","article-title":"High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: a systematic review","volume":"97","author":"Gerritse","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025051309001693500_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-024-00616-8","article-title":"Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation","volume":"10","author":"Johansson","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2025051309001693500_bib56","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.annonc.2021.07.017","article-title":"Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy","volume":"32","author":"Jerusalem","year":"2021","journal-title":"Ann Oncol"},{"key":"2025051309001693500_bib57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025051309001693500_bib58","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2025051309001693500_bib59","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"2025051309001693500_bib60","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025051309001693500_bib61","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0475\/3554163\/crc-24-0475.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/3\/497\/3563249\/crc-24-0475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/3\/497\/3563249\/crc-24-0475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T09:00:29Z","timestamp":1747126829000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/3\/497\/754459\/OATP1B-type-Transport-Function-Is-a-Determinant-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0475","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29051006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684278","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684290","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051000","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051012","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675824","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675812","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051009","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051003","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675809","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675815","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28675827","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7740543","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}